Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−17 JPY
−1.17 B JPY
72.00 K JPY
83.43 M
About BRIGHTPATH BIOTHERAPEUTICS CO LTD
Sector
CEO
Kenichi Nagai
Headquarters
Kanagawa
Website
Founded
2003
ISIN
JP3274140007
FIGI
BBG00B07B4D4
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer peptide vaccines, which constitute one form of cancer immunotherapy. It has developed ITK-1, a cancer peptide vaccine, which is in phase III clinical study to treat prostate cancer; and GRN-1201 that is in phase II clinical study for the treatment of non-small cell lung cancer, as well as in phase I clinical study to treat melanoma. The company’s products include GRN-1301, a drug resistant tumor-derived neo-antigen for the treatment of non-small cell lung cancer; and iPS-NKT, an induced pluripotent stem cell derived regenerated NKT cell therapy. BrightPath Biotherapeutics was founded by Ito Kyogo on May 8, 2003 and is headquartered in Kanagawa, Japan.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 4594 is 44 JPY — it has decreased by −4.35% in the past 24 hours. Watch BRIGHTPATH BIOTHERAPEUTICS CO LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange BRIGHTPATH BIOTHERAPEUTICS CO LTD stocks are traded under the ticker 4594.
4594 stock has fallen by −8.33% compared to the previous week, the month change is a −10.20% fall, over the last year BRIGHTPATH BIOTHERAPEUTICS CO LTD has showed a −47.62% decrease.
4594 reached its all-time high on Apr 21, 2016 with the price of 2,229 JPY, and its all-time low was 41 JPY and was reached on Oct 28, 2024. View more price dynamics on 4594 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4594 stock is 4.55% volatile and has beta coefficient of 1.30. Track BRIGHTPATH BIOTHERAPEUTICS CO LTD stock price on the chart and check out the list of the most volatile stocks — is BRIGHTPATH BIOTHERAPEUTICS CO LTD there?
Today BRIGHTPATH BIOTHERAPEUTICS CO LTD has the market capitalization of 3.81 B, it has decreased by −4.00% over the last week.
Yes, you can track BRIGHTPATH BIOTHERAPEUTICS CO LTD financials in yearly and quarterly reports right on TradingView.
BRIGHTPATH BIOTHERAPEUTICS CO LTD is going to release the next earnings report on Feb 7, 2025. Keep track of upcoming events with our Earnings Calendar.
4594 net income for the last quarter is −208.31 M JPY, while the quarter before that showed −330.42 M JPY of net income which accounts for 36.95% change. Track more BRIGHTPATH BIOTHERAPEUTICS CO LTD financial stats to get the full picture.
No, 4594 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 24.00 employees. See our rating of the largest employees — is BRIGHTPATH BIOTHERAPEUTICS CO LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BRIGHTPATH BIOTHERAPEUTICS CO LTD EBITDA is −1.15 B JPY, and current EBITDA margin is −1.60 M%. See more stats in BRIGHTPATH BIOTHERAPEUTICS CO LTD financial statements.
Like other stocks, 4594 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BRIGHTPATH BIOTHERAPEUTICS CO LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BRIGHTPATH BIOTHERAPEUTICS CO LTD technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BRIGHTPATH BIOTHERAPEUTICS CO LTD stock shows the strong sell signal. See more of BRIGHTPATH BIOTHERAPEUTICS CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.